- Novo Nordisk's Victoza helps patients achieve blood-sugar control when switching from exenatide or sitagliptin
- Adherence among chronic disease patients can lead to big savings
- Decision Resources: Bydureon could promote weight loss among patients
- Study: Metformin best first-line diabetes treatment
- Study: Hemoglobin A1C may not effectively diagnose kids with diabetes
LISBON, Portugal — A drug made by Boehringer Ingelheim and Eli Lilly showed "meaningful and durable" reductions in blood sugar in adults with Type 2 diabetes, according to results of a late-stage clinical trial presented Friday at a conference in Europe.
BI and Lilly presented data from their 102-week phase-3 study of Tradjenta (linagliptin) at the European Association for the Study of Diabetes' 47th annual meeting in Lisbon, Portugal, showing that the drug lowered HbA1C levels by 0.8% over the long term. The drug is marketed in Europe under the name Trajenta.
"These results show that the efficacy achieved by linagliptin is reliable and meaningful in a clinical setting, but also that it is durable over the long term," said David Owens, a medical professor at Cardiff University School of Medicine, in Wales.
In the 2,121-patient study, patients were given Tradjenta, Tradjenta with metformin or Takeda's Actos (pioglitazone) or Trajdenta with metformin and sulphonylurea.